Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas
- 595 Downloads
Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas is classified as a variant of intraductal papillary mucinous neoplasm (IPMN) in the WHO guidelines. However, the neoplastic cells of IOPNs are unique, with distinctive architecture/oncocytic cytoplasm. Although molecular/immunohistochemical features of other IPMN variants have been extensively studied, those of IOPNs have not been well characterized. Expression profile of antibodies associated with genetic alterations previously described for ductal adenocarcinomas (DAs) and IPMNs (SMAD4/β-catenin/p53/mesothelin/claudin-4) as well as antibodies to mucins and differentiation markers [MUC1/MUC2/MUC5AC/MUC6/CDX2/hepatocyte paraffin-1 (HepPar-1)] was investigated in 24 IOPNs and 22 IPMNs to assess the similarities/differences between these tumors. Expression of mesothelin and claudin-4 was dissimilar between these tumor types: A higher proportion of IOPNs labeled with mesothelin [21/24 (87.5 %) of IOPNs, 6/22 (27 %) of IPMNs, p < 0.001], while the reverse was true for claudin-4 [2/23 (9 %) of IOPNs, 9/22 (41 %) of IPMNs, p = 0.01]. The results of immunolabeling for SMAD4/β-catenin/p53 were similar in both: None of the cases showed SMAD4 loss in the intraductal components, and only 1/21 (5 %) of IOPNs and 2/22 (9 %) of IPMNs revealed abnormal β-catenin expression (p = 0.49). Nuclear p53 accumulation was seen mostly in architecturally complex/high-grade dysplasia areas in both. Immunolabeling for MUC proteins showed that almost all lesions expressed MUC5AC. Twelve of the 24 (50 %) IOPNs and 6/22 (27 %) of IPMNs (p = 0.11) labeled for MUC1, whereas 7/24 (29 %) of IOPNs and 10/22 (45 %) of IPMNs labeled for MUC2 (p = 0.25). MUC6 was expressed in 8/9 (89 %) of IOPNs (strong) and 6/21 (29 %) of IPMNs (weak) (p = 0.002). Fourteen of the 23 (61 %) IOPNs and 4/22 (18 %) of IPMNs labeled for HepPar-1 (p = 0.003). These results show that IOPNs have distinct immunoprofile and provide support for the proposition that IOPN is a distinct entity developing through a mechanism different from other pancreatic ductal neoplasms.
KeywordsPancreas IOPN IPMN Immunohistochemistry Oncocytic
The authors thank Ms. Tanisha Daniel for her assistance during manuscript preparation and Allyne Manzo and Lorraine Corsale for their assistance with the figures.
Compliance with ethical standards
The study was performed with approval of the Institutional Review Board and in accordance with Health Insurance Portability and Accountability Act regulations.
This work has been supported by the Cancer Center Support Grant (CCSG)/Core Grant/P30 CA008748.
Conflict of interest
The authors declare no conflict of interest.
- 2.Adsay NV, Kloeppel G, Fukushima N, Offerhaus GJ, Furukawa N (2010) Intraductal neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors. WHO Press, Lyon, pp. 304–313Google Scholar
- 10.Luttges J, Zamboni G, Longnecker D, Kloppel G (2001) The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 25(7):942–948PubMedCrossRefGoogle Scholar
- 18.Basturk O, Khayyata S, Klimstra DS, et al. (2010) Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol 34(3):364–370PubMedPubMedCentralCrossRefGoogle Scholar
- 40.Basturk O, Tan M, Bhanot U et al (2016) The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod PatholGoogle Scholar
- 41.Adsay V, Mino-Kenudson M, Furukawa T, et al. (2016) Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other Tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of Verona consensus meeting. Ann Surg 263(1):162–177PubMedCrossRefGoogle Scholar
- 44.Askan G, Klimstra D, Adsay V, et al. (2016) “Oncocytic-type” of intraductal papillary mucinous neoplasm (IPMN): an analysis of 25 cases (abstract). Lab Investig 96(S1):1740Google Scholar
- 54.Maitra A, Iacobuzio-Donahue C, Rahman A, et al. (2002) Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 118(1):52–59PubMedCrossRefGoogle Scholar
- 58.Abraham SC, Wu TT, Klimstra DS, et al. (2001) Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 159(5):1619–1627PubMedPubMedCentralCrossRefGoogle Scholar